Financial Performance - Revenue for the year ended December 31, 2023, was RMB 4,856,806 thousand, an increase of 12.2% compared to RMB 4,329,075 thousand in 2022[1] - The net loss for the year narrowed to RMB 230,868 thousand from RMB 2,842,275 thousand, a reduction of 91.9%[1] - Adjusted net loss (non-IFRS measure) was RMB 106,618 thousand, a decrease of 17.2% from RMB 128,698 thousand in the previous year[1] - Adjusted net loss margin improved to (2.2%) from (3.0%), an improvement of 0.8 percentage points[1] - Gross profit for the year was RMB 1,510,671 thousand, compared to RMB 1,449,670 thousand in 2022[3] - The company reported a pre-tax loss of RMB 225,809,000 for the year ended December 31, 2023, compared to a loss of RMB 2,833,395,000 for the previous year, indicating a significant improvement[21] - Total revenue for the year ended December 31, 2023, reached RMB 406,186,000, representing a growth of 14.7% compared to RMB 353,870,000 in 2022[26] - Total revenue for the year ended December 31, 2023, increased to RMB 4,856.8 million, a year-on-year growth of 12.2% from RMB 4,329.1 million in 2022[32] - Net loss narrowed by 91.9% to RMB 230.9 million, with an adjusted loss rate of 2.2%, a decrease of 0.8 percentage points year-on-year[32] Revenue Breakdown - Revenue from pharmaceutical and healthcare business reached RMB 4,717,592 thousand, up from RMB 4,201,618 thousand in the previous year, reflecting a growth of 12.3%[14] - Online direct sales revenue was RMB 3,527.9 million, reflecting a year-on-year increase of 14.1% from RMB 3,091.0 million[34] - Distribution business revenue rose to RMB 545.8 million, a 25.0% increase from RMB 436.6 million in 2022[36] - Offline retail revenue decreased to RMB 643.9 million, down 4.5% from RMB 674.0 million in 2022[37] - Other business revenue grew to RMB 139.2 million, a year-on-year increase of 9.2% from RMB 127.5 million[38] Expenses and Cost Management - Research and development expenses decreased to RMB 64,981 thousand from RMB 88,951 thousand, reflecting a focus on cost management[3] - Total employee benefits expenses decreased to RMB 530,415,000 in 2023 from RMB 619,446,000 in 2022, reflecting a reduction of approximately 14.3%[4] - Cost of revenue increased by 16.2% from RMB 2,879.4 million in 2022 to RMB 3,346.1 million in 2023, primarily due to increased sales in the pharmaceutical and healthcare business[44] - Fulfillment expenses rose by 10.8% from RMB 444.2 million in 2022 to RMB 492.1 million in 2023, while the percentage of fulfillment expenses to revenue decreased from 10.3% to 10.1%[46] - Sales and marketing expenses increased by 7.1% from RMB 908.2 million in 2022 to RMB 972.7 million in 2023, with the percentage of these expenses to revenue decreasing from 21.0% to 20.0%[47] - R&D expenses decreased by 26.9% from RMB 89.0 million in 2022 to RMB 65.0 million in 2023, with the percentage of R&D expenses to revenue dropping from 2.1% to 1.3%[48] - General and administrative expenses fell by 22.7% from RMB 334.5 million in 2022 to RMB 258.7 million in 2023, with the percentage of these expenses to revenue decreasing from 7.7% to 5.3%[49] Assets and Liabilities - Total assets as of December 31, 2023, were RMB 3,064,768 thousand, down from RMB 3,297,475 thousand in 2022[4] - Total liabilities decreased to RMB 1,027,873 thousand from RMB 1,098,279 thousand, indicating improved financial stability[5] - Cash and cash equivalents were RMB 1,185,898 thousand, slightly down from RMB 1,210,949 thousand in the previous year[4] - Trade receivables increased to RMB 114,438,000 as of December 31, 2023, compared to RMB 106,125,000 in 2022, showing an increase of 7.3%[23] - Total liabilities for trade and other payables amounted to RMB 774,084,000 as of December 31, 2023, slightly up from RMB 772,817,000 in 2022[25] Strategic Initiatives - The company continues to focus on expanding its pharmaceutical and healthcare services within China[6] - The company plans to enhance its digital health services and supply chain collaboration, focusing on integrating data analysis to improve user experience[28] - Establishment of multiple digital disease specialty centers and remote pharmaceutical service platforms to meet user needs for health management and medication guidance[29] - Implementation of online payment solutions in Shanghai, creating a closed-loop service from drug sales to insurance settlement and home delivery[30] - The company aims to strengthen its cold chain logistics capabilities to ensure safe and quality delivery of pharmaceuticals[30] - The year 2024 is identified as a critical year for the company's five-year plan, focusing on digital transformation and expanding core business areas[31] - Continuous innovation in product offerings and services to meet diverse user needs and enhance the overall health management ecosystem[31] Corporate Governance and Compliance - The company has committed to high standards of corporate governance and has adopted the corporate governance code as per the Hong Kong Stock Exchange[69] - The company plans to continue reviewing its corporate governance practices to ensure compliance with the corporate governance code[69] - The audit committee has reviewed the audited consolidated financial statements for the year ending December 31, 2023[74] - The company has established an audit committee to oversee financial reporting processes and risk management systems[73] Other Financial Information - The company recorded a total tax expense of RMB 9,641,000 for 2023, a decrease from RMB 10,128,000 in 2022, reflecting a reduction of 4.8%[20] - Other income increased by 70.3% from RMB 28.9 million for the year ended December 31, 2022, to RMB 49.1 million for the year ended December 31, 2023, primarily due to increased interest income[52] - The company raised approximately HKD 341.6 million from its global offering, with 45% allocated for business expansion and technology system optimization[68] - As of December 31, 2023, the company had utilized HKD 147.7 million of the raised funds, leaving HKD 84.7 million remaining[68] - The company has adopted a share incentive plan involving a total of 87,993,330 shares, representing about 6.56% of the issued share capital as of December 31, 2023[67]
叮当健康(09886) - 2023 - 年度业绩